Drug Profile
Lamivudine/lopinavir/ritonavir
Alternative Names: Lopinavir/ritonavir/3TCLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Amides; Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Pyrimidine nucleosides; Pyrimidinones; Small molecules; Thiazoles
- Mechanism of Action HIV protease inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in HIV-1-infections(Combination therapy) in USA (PO, Tablet)
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 15 Jul 2011 Clinical trials in HIV-1 infections in USA (PO)